Aktis Oncology (NASDAQ:AKTS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Aktis Oncology (NASDAQ:AKTS) has been given an average rating of “Moderate Buy” by the ten analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $35.00.

A number of equities research analysts recently issued reports on AKTS shares. Wall Street Zen lowered Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. BMO Capital Markets started coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. HC Wainwright lifted their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, Raymond James Financial began coverage on Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 target price for the company.

Aktis Oncology Stock Performance

AKTS stock opened at $25.78 on Monday. The stock has a market cap of $1.39 billion and a PE ratio of -31.44. Aktis Oncology has a 12 month low of $14.72 and a 12 month high of $34.19. The company has a 50-day moving average price of $25.81 and a 200 day moving average price of $21.52.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The company had revenue of $3.38 million for the quarter, compared to the consensus estimate of $2.70 million. Sell-side analysts forecast that Aktis Oncology will post -1.8 EPS for the current year.

Insider Transactions at Aktis Oncology

In other news, Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the completion of the transaction, the director directly owned 3,506 shares of the company’s stock, valued at approximately $86,107.36. The trade was a 58.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Institutional Trading of Aktis Oncology

A number of institutional investors have recently made changes to their positions in AKTS. State of Wyoming acquired a new stake in Aktis Oncology during the 2nd quarter valued at approximately $32,000. AXQ Capital LP acquired a new stake in Aktis Oncology during the second quarter valued at $226,000. Susquehanna International Group LLP acquired a new position in shares of Aktis Oncology in the second quarter worth about $278,000. California State Teachers Retirement System purchased a new position in Aktis Oncology during the second quarter worth approximately $288,000. Finally, Deutsche Bank AG increased its stake in shares of Aktis Oncology by 49.3% in the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after acquiring an additional 6,942 shares during the last quarter. Institutional investors and hedge funds own 28.84% of the company’s stock.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.